Biomarker-Defined Metastatic Solid Tumors
Too many loved ones live with uncertainty.
Let’s find answers.
Precision medicine is transforming how we treat cancer. We know that a patient’s response to treatment can depend on the genetic makeup of their cancer and are applying a precision medicine approach to develop new treatments for a number of highly prevalent, biomarker-defined metastatic cancers. Our ambition is for patients with cancer to lead longer, better lives.
Colorectal and pancreatic cancer
Phase 1b trial is evaluating brimarafenib, an investigational, selective RAF dimer inhibitor, in combination with panitumumab, a monoclonal antibody targeting Epidermal Growth Factor Receptor, in patients with colorectal and pancreatic cancer with known MAPK pathway mutations.